Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
P/E ratio for Sight Sciences, Inc. (SGHT)
P/E ratio as of 2023: -4.52
According to Sight Sciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.52. At the end of 2022 the company had a P/E ratio of -6.77.
P/E ratio history for Sight Sciences, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.52 |
| 2022 | -6.77 |
| 2021 | -13.26 |
| 2020 | -45.16 |
| 2019 | -60.56 |
| 2018 | -75.49 |